Tumour devascularisation as a potential immunotherapeutic strategy

Complete tumour devascularisation (CTD) is a surgical technique which entails the complete disruption by ligation or cutting of afferent and efferent tumour vasculature which remains in situ. In some animal models, CTD induces immune responses that lead to regression of distant metastases and protec...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchler, Tomas, Vasek, Pavel, Spisek, Radek, Skrobanek, Pavel, Horejsi, Vaclav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Point-of-View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287775/
https://www.ncbi.nlm.nih.gov/pubmed/30546967
http://dx.doi.org/10.1080/2162402X.2018.1526614
_version_ 1783379682671984640
author Buchler, Tomas
Vasek, Pavel
Spisek, Radek
Skrobanek, Pavel
Horejsi, Vaclav
author_facet Buchler, Tomas
Vasek, Pavel
Spisek, Radek
Skrobanek, Pavel
Horejsi, Vaclav
author_sort Buchler, Tomas
collection PubMed
description Complete tumour devascularisation (CTD) is a surgical technique which entails the complete disruption by ligation or cutting of afferent and efferent tumour vasculature which remains in situ. In some animal models, CTD induces immune responses that lead to regression of distant metastases and protective immunity.
format Online
Article
Text
id pubmed-6287775
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-62877752018-12-13 Tumour devascularisation as a potential immunotherapeutic strategy Buchler, Tomas Vasek, Pavel Spisek, Radek Skrobanek, Pavel Horejsi, Vaclav Oncoimmunology Point-of-View Complete tumour devascularisation (CTD) is a surgical technique which entails the complete disruption by ligation or cutting of afferent and efferent tumour vasculature which remains in situ. In some animal models, CTD induces immune responses that lead to regression of distant metastases and protective immunity. Taylor & Francis 2018-10-11 /pmc/articles/PMC6287775/ /pubmed/30546967 http://dx.doi.org/10.1080/2162402X.2018.1526614 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Point-of-View
Buchler, Tomas
Vasek, Pavel
Spisek, Radek
Skrobanek, Pavel
Horejsi, Vaclav
Tumour devascularisation as a potential immunotherapeutic strategy
title Tumour devascularisation as a potential immunotherapeutic strategy
title_full Tumour devascularisation as a potential immunotherapeutic strategy
title_fullStr Tumour devascularisation as a potential immunotherapeutic strategy
title_full_unstemmed Tumour devascularisation as a potential immunotherapeutic strategy
title_short Tumour devascularisation as a potential immunotherapeutic strategy
title_sort tumour devascularisation as a potential immunotherapeutic strategy
topic Point-of-View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287775/
https://www.ncbi.nlm.nih.gov/pubmed/30546967
http://dx.doi.org/10.1080/2162402X.2018.1526614
work_keys_str_mv AT buchlertomas tumourdevascularisationasapotentialimmunotherapeuticstrategy
AT vasekpavel tumourdevascularisationasapotentialimmunotherapeuticstrategy
AT spisekradek tumourdevascularisationasapotentialimmunotherapeuticstrategy
AT skrobanekpavel tumourdevascularisationasapotentialimmunotherapeuticstrategy
AT horejsivaclav tumourdevascularisationasapotentialimmunotherapeuticstrategy

Ejemplares similares